Growth characteristics of myelodysplastic CD34+ cells

Leukemia & Lymphoma
K Sawada

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders of hematopoiesis entailing hyperproliferative and ineffective hematopoiesis associated with morphologic evidence of marrow cell dysplasia resulting in refractory cytopenia(s), and an increased risk of transformation into acute myeloblastic leukemia (AML). The administration of colony-stimulating factor(s) (CSFs) to patients with MDS increased blood neutrophil concentrations, in most patients, and it was anticipated to be of benefit to prevent infections. The progression to AML while being treated with CSFs has come under close scrutiny. In vitro studies are expected to produce more pertinent criteria for selection of patients who are likely to benefit, as well as the overall benefits of various therapies. For this purpose, in vitro colony assays are an excellent approach for investigation of the biologic characteristics of MDS progenitor cells. The stem cell phenotype CD34 is the one of the best markers of progenitor cells, and can be used for the purification of these cells to unify levels of maturation; a direct comparison of proliferative and differentiative capacity of MDS progenitor cells with normal CD34+ cells can thus be made. The properties of MDS C...Continue Reading

References

Jan 1, 1979·Leukemia Research·G SpitzerK B McCredie
Jan 1, 1979·Leukemia Research·D S VermaK B McCredie
Feb 1, 1978·The Journal of Experimental Medicine·D G NathanD E Housman
Jun 1, 1979·The American Journal of Medicine·P L Greenberg, B Mara
Mar 1, 1978·Scandinavian Journal of Haematology·A FailleY Najean
Aug 10, 1978·Nature·J T PrchalJ F Prchal
Mar 1, 1976·The Journal of Small Animal Practice·W I Morrison, N G Wright
Jul 1, 1977·The Journal of Experimental Zoology·R Barra, J C Hall
Oct 1, 1991·Journal of Cellular Physiology·K SawadaS Nakagawa
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockJ U Gutterman
May 1, 1990·American Journal of Hematology·D GuyotatD Fiere
May 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A ThompsonA Fefer
Jul 1, 1988·Science·G J SpangrudeI L Weissman
May 24, 1973·The New England Journal of Medicine·D W Golde, M J Cline
Sep 1, 1972·British Journal of Haematology·J S Senn, P H Pinkerton
Aug 1, 1970·Journal of Cellular Physiology·B L Pike, W A Robinson
Jan 1, 1984·The Journal of Clinical Investigation·J L AbkowitzJ W Adamson
Aug 1, 1980·Annals of Internal Medicine·H P Koeffler, D W Golde
Jun 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·T Nakahata, M Ogawa
Sep 1, 1993·British Journal of Haematology·D BowenK Resser
Jan 1, 1993·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·T PietschK Welte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.